A small Belgian study of people with dementia on low-dose antipsychotics found that abrupt stoppage of the medication, rather than tapering, is a possible solution. Eighty-five percent of 40 patients who stopped abruptly were fine a month later.
Pharmaceutical giant GlaxoSmithKline will stop paying healthcare professionals to speak about its products, and will alter other marketing and compensation practices that are common in the industry but derided by critics, the company announced Tuesday.
The second annual McKnight's Long-Term Care News Excellence in Technology Awards begged the question: How can you compare to last year's storied winners?
More than 6,000 skilled nursing facilities achieved notable gains in the first year of the American Health Care Association's Quality Initiative, the provider association announced yesterday.
From reducing off-label use of antipsychotics to better antibiotic stewardship, medication management is at the forefront of today's long-term care challenges. And Golden LivingCenter-Indianapolis is in the vanguard of facilities tackling this challenge in innovative ways. For this, the skilled nursing facility received top honors in the McKnight's Excellence in Technology awards.
Providers reveal strategies for reducing unneccessary antipsychotics use for residents with dementia, and meeting industry-wide medication reduction goals
MASSACHUSETTS — An ongoing debate over nursing homes' use of antipsychotics flared in July during a meeting of the Joint Committee on Elder Affairs.
Nursing homes have made strides toward reducing antipsychotic medication use among residents with dementia, according to new figures from the Centers for Medicare & Medicaid Services and the American Health Care Association/National Center for Assisted Living.
Haloperidol, a common antipsychotic, is no more effective than a placebo in treating delirium in critically ill patients, according to a new study.
Q: The Alzheimer's Association annual conference took place in mid-July. As an expert in the disease, what did you find the most noteworthy takeaway?
A government investigation into nursing homes' antipsychotic prescribing practices will not move forward due to budget and staff cuts, according to nonprofit investigative news organization The Center for Public Integrity.
Most nursing home medication errors involve analgesics and sedatives, and these drugs are likely to account for errors regardless of how frequently they are administered, according to recently published research.
Skilled nursing providers fell short of reaching a 15% reduction in off-label antipsychotic use by the end of 2012, the American Health Care Association formally announced last month. However, AHCA did renew the goal for 2013, and members also performed better in the reductions than nursing providers overall.
Drugmaker AstraZeneca recently settled a lawsuit with the state of Kentucky over allegations of improperly marketing its atypical antipsychotic drug Seroquel. Under the settlement, the London-based pharmaceutical company will pay the Bluegrass State $5.5 million.
The former director of nursing at a California nursing home was sentenced Wednesday to three years in prison for administering powerful drugs to subdue residents.
The U.S. Senate did not approve legislation that would strengthen regulations for antipsychotic use in nursing homes, despite overwhelmingly passing a bill it was attached to on Thursday.
While antipsychotic drug use overuse has decreased since 2005, nearly a quarter of U.S. nursing homes are still giving many residents the medications against recommendations, a Boston Globe analysis reveals.
Government prosecutors rejected a proposed settlement worth roughly $1 billion with pharmaceutical giant Johnson & Johnson over questionable marketing tactics for the antipsychotic Risperdal.
The Senate Special Committee on Aging will hold a hearing today about the use of antipsychotics in nursing homes.The hearing, titled "Overprescribed: The Human and Taxpayers' Costs of Antipsychotics in Nursing Homes," will be at 2 pm ET.
Pharmaceutical giant AstraZeneca has agreed to pay $520 million to end a federal investigation into its alleged illegal marketing of the drug Seroquel for off-label uses, according to reports from Washington.
The U.S. Department of Justice on Friday filed a lawsuit against Johnson & Johnson for its alleged role in a kickback scheme with Omnicare, the nation's largest long-term care pharmacy chain.